Received: 18 June 2022
Accepted: 12 October 2022
First Online: 21 October 2022
: This retrospective cohort study was approved by the ethics committee of Akita University (approval number: 2762). All methods in the present study were carried out in accordance with relevant guidelines and regulations and the ethical standards laid down in the 1964 Helsinki declaration and its later amendments. Informed consent was obtained from all the study subjects in the form of opt-out on the website and approved by the ethics committee of Akita University.
: Not applicable.
: Masahiro Takeshima has received speaker’s honoraria from Takeda Pharmaceutical, MSD, Daiichi Sankyo Company, Sumitomo Dainippon Pharma, Meiji Seika Pharma, Viatris Pharmaceuticals Japan, and Yoshitomi Pharmaceutical, and research grants from Otsuka Pharmaceutical, EISAI, Shionogi and the Japanese Ministry of Health, Labour and Welfare (R3-21GC1016) outside the submitted work. Kazuo Mishima has received speaker’s honoraria from EISAI Co., Ltd., Nobelpharma Co., Ltd., and MSD Inc., and research grants from the Japanese Ministry of Health, Labour and Welfare (19GC1012, 21GC0801) outside the submitted work. The other authors declare no conflicts of interest.